Efficacy and Safety of Kukoamine B Mesilate in Sepsis Patients

Sepsis Clinical Trial

Official title:

Efficacy and Safety of Kukoamine B Mesilate in Sepsis Patients: a Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 2 Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04803955
• Other study ID #: HR-KB201
• Status: Recruiting
• Phase: Phase 2
• Start date: May 15, 2021
• Est. completion date: June 30, 2024

Study information

• Verified date: April 2024
• Source: Tianjin Chasesun Pharmaceutical Co., LTD
• Contact: Shuai Chen, Bachelor
• Phone: +86 022-59623160
• Email: 18600050139[@]126.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Phase II study of Kukoamine B Mesilate in Sepsis Patients

Description:

To Assess Efficacy,Safety,Pharmacokinetics of Kukoamine B Mesilate in Sepsis Patients

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 424
• Est. completion date: June 30, 2024
• Est. primary completion date: May 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

• (1) The age of = 18 years of age and = 85 years of age, gender is not limited;
• (2) Meeting the diagnostic criteria for sepsis 3.0, i.e. sequential organ failure score (SOFA) increased by =2 points from baseline for patients with confirmed or suspected infection;
• (3) Confirmed or suspected bacterial infection (Pulmonary, abdominal,urinary system or hematogenous infections);
• (4) Infection-related organ failure does not exceed 48 hours; organ failure is defined as circulation, (SOFA) = 3 points in at least one organ or system of the respiratory, kidney, liver, coagulation and central nervous system;
• (5) Childbearing age within six months without child care plan and agreed to take effective measures during the study of contraception;
• (6) Patients or guardians signed informed consent.

Exclusion Criteria:

• (1) Pregnancy or lactation women;
• (2) Patients are expected to live less than 48 hours;
• (3) Patients had poor control of malignant tumor, end-stage lung disease and other end-stage diseases, or had acardiac arrest,acute pulmonary embolism,blood transfusion response and acute coronary syndrome within 4 weeks prior to enrollment;
• (4) The patient has the following chronic organ dysfunction or immunosuppression (based on the chronic health scoring assessment of the APACHE II score) : 1) heart: New York heart association cardiac function IV; 2) breathing: chronic obstructive, obstructive, or vascular lung disease can lead to severe restrictions on activities, i.e. the inability to go upstairs or to do housework; Or clear chronic hypoxia, CO2 retention, secondary real erythrocyte, severe pulmonary hypertension (mPAP> 40 mmHg) or respiratory muscle dependence; 3) kidneys: receiving long-term dialysis; 4) liver: liver cirrhosis confirmed by biopsy and clear portal hypertension; The upper digestive tract hemorrhage caused by portal hypertension; Or previous liver failure/hepatic encephalopathy/hepatic coma; 5) of immune function: accept the treatment of impact resistance to infection, such as immune suppression therapy, chemotherapy, radiotherapy or chemotherapy within 6 months, long-term (continuous use =3 weeks) use of glucocorticoids or recent (within 5 days before screening) cumulative use of prednisone or equivalent dose =100mg , or sickness impact resistance to infection, such as leukemia, lymphoma and AIDS);
• (5) Previous solid organ or bone marrow transplantation;
• (6) Plant survival status;
• (7) Confirmed or highly suspected of acute infectious diseases such as viral hepatitis activity , or clinically confirmed active tuberculosis;
• (8) Patients with sinus bradycardia (less than 60 per minute);
• (9) Uncontrolled bleeding in the past 24 hours(Clinical judgment requires transfusion support);
• (10) Large area burns or chemical burns (III degree burns area > 30% BSA);
• (11) The average arterial pressure was < 65 mmHg after adequate liquid resuscitation and vasoactive drug therapy;
• (12) Acute myeloid hematopoiesis was characterized by a lack of severe granulocytes (ANC < 500 / mm3);
• (13) Allergic to the active ingredient or its auxiliary materials;
• (14) The medication patients are using may severely affect the metabolism of the drug;
• (15) Patients and (or) guardians have signed a Do Not Rescue (DNR), or decided to withdraw life support (withdraw) or restrict life support for the intensity (withhold) and sign the informed consent form;
• (16) Participated in clinical intervention test in 3 months;
• (17) The subject is a researcher or his immediate family member, or may have improper informed consent;
• (18) The investigator considers it inappropriate for the patient to participate in this test.

Related Conditions & MeSH terms

• Sepsis
• Toxemia

Intervention

Drug:
• 16mg,KB
16mg,Q8h±3min,Day1-Day7
• Placebos
16mg,Q8h±3min,Day1-Day7

Locations

Country	Name	City	State
China	Peking Union Medical College Hospital	Beijing	Beijing

Sponsors (2)

Lead Sponsor	Collaborator
Tianjin Chasesun Pharmaceutical Co., LTD	Southwest Hospital, China

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Area under the curve at steady state (AUCss)	determination of area under curve	Day 1 and Day 7
Other	Peak plasma concentration at steady state (Cmaxss)	determination of Cmax	Day 1 and Day 7
Other	Trough plasma concentration at steady state (Cminss)	determination of Cmin	Day 1 and Day 7
Other	Correlation between the exposure of Kukoamine B Mesilate and its efficacy	Correlation between the exposure of Kukoamine B Mesilate and change in SOFA scale from baseline.	Day 8 after the first dose (Within 24 hours after the last dose on day 7)
Other	Correlation between the exposure of Kukoamine B Mesilate and hepatic-related treatment-related adverse events	Correlation between the exposure of Kukoamine B Mesilate and hepatic-related treatment-related adverse events of interest as assessed by CTCAE v5.0.	Day 1 to Day 8
Primary	Delta SOFA (?SOFA)	Change in SOFA scale from baseline.	Day 8 after the first dose (Within 24 hours after the last dose on day 7)
Secondary	Clinical Outcome Composite Endpoint	Proportion of patients with 28-day all-cause deaths and continuing ICU stay after the first dose.	28 days after the first dose
Secondary	Proportion of patients with 7-day all-cause deaths	Proportion of patients with 7-day all-cause deaths after first dose.	7 days after the first dose
Secondary	Proportion of patients transferred out of ICU	Proportion of patients transferred out of ICU within 7 days after first dose.	7 days after the first dose
Secondary	Quantification of IL-6	Change of IL-6 from baseline on day 2,4,8 after first dose (Within 24 hours after the last dose on day 7).	Day 2, 4 , 8 after the first dose (Within 24 hours after the last dose on day 7)
Secondary	Delta SOFA (?SOFA)	Change in SOFA scale from baseline on day 1,3 ,5 after first dose.	Day 1, 3, 5 after the first dose
Secondary	Duration of use and abstention of life support treatment	Duration of use and abstention of life support treatment (vasoactive drugs, mechanical ventilation, CRRT) .	28 days after the first dose
Secondary	Duration of ICU stay and absence	Duration of ICU stay and absence within 28 days after the first dose.	28 days after the first dose
Secondary	Rate of adverse events/serious adverse events	Observe all the participants in any adverse events occurred during the period of clinical research, including clinical symptoms and signs of life, an abnormal in laboratory tests, record its clinical characteristics, severity, occurrence time, duration, treatment and prognosis, and determine its and the correlation between test drugs. CTCAE v5.0 standard was used to evaluate drug safety.	From date of singing informed consent until the 29 days after the first dose